NDAORALLIQUIDPriority Review
Approved
Aug 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMAGENT (perflubron) is an oral liquid diagnostic imaging agent approved in 1993 for enhancing ultrasound visualization. It is a perfluorocarbon-based contrast medium that functions as an echocardiographic agent. The drug works by improving acoustic backscatter to enhance cardiac and vascular imaging quality.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, suggesting downsizing commercial infrastructure and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IMAGENT presents limited career growth opportunities due to approaching loss of exclusivity and zero linked job openings. Roles available are primarily defensive—focused on pricing negotiations, formulary retention, and transition planning rather than product expansion or innovation.
Brand ManagerProduct Manager
Worked on IMAGENT at Alliance Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.